NCT00257478View on ClinicalTrials.gov

A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Study Completion Date

March 31, 2007

Conditions
Prostate CancerCancer of ProstateProstatic CancerCancer of the Prostate
Interventions
DRUG

YM155

Trial Locations (9)

10016

New York

10461

The Bronx

19111

Philadelphia

78229

San Antonio

83814

Coeur d'Alene

85724

Tuscon

90033

Los Angeles

Unknown

Amsterdam

SM2 5Pt

Sutton

Sponsors
All Listed Sponsors
collaborator

Astellas Pharma US, Inc.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY

NCT00257478 - A Study for the Treatment of Hormone Refractory Prostate Cancer (HRPC) in Patients Previously Treated With Chemotherapy | Biotech Hunter | Biotech Hunter